WAYNE, PA — Palvella Therapeutics Inc. (Nasdaq: PVLA) said it remains on track to submit a New Drug Application in the second half of 2026 for its lead therapy targeting microcystic lymphatic malformations, a rare disease with no FDA-approved treatment options, following a pre-submission meeting with federal regulators.
The meeting with the U.S. Food and Drug Administration focused on the company’s planned application package for QTORIN 3.9% rapamycin anhydrous gel, a topical therapy being developed for patients with microcystic lymphatic malformations, according to the company.
The regulatory update is significant because approval would position QTORIN rapamycin to become the first FDA-approved therapy for the condition, potentially giving Palvella a first-mover advantage in a market the company estimates includes more than 30,000 patients in the United States.
Microcystic lymphatic malformations are chronic vascular disorders that can cause recurrent leaking, bleeding, infections, pain and functional impairment. Current treatment options generally consist of surgical interventions, procedural management and off-label therapies.
Palvella indicated that the FDA reviewed the proposed evidence package for the application, including efficacy and safety data from the Phase 3 SELVA trial and supportive findings from an earlier Phase 2 study.
The company stated that the application is expected to include blinded independent review data and photographic evidence from all patients enrolled in the Phase 3 study, along with published literature and real-world clinical experience involving off-label rapamycin use.
Based on discussions with regulators and the official meeting minutes, Palvella plans to proceed with the filing using its existing clinical data package and does not expect to conduct an additional efficacy study before submission.
Chief Executive Officer Wes Kaupinen said the company remains aligned with previously disclosed timelines for the application.
“We are pleased with the outcome of our pre-NDA meeting with FDA and encouraged as we continue advancing toward submission of an NDA for QTORIN rapamycin in microcystic lymphatic malformations in the second half of 2026,” Kaupinen said.
QTORIN rapamycin has previously received Breakthrough Therapy, Fast Track and Orphan Drug designations from the FDA for the treatment of microcystic lymphatic malformations. The therapy has also received support through an FDA Orphan Products Development grant.
For Palvella, the filing represents a critical regulatory milestone as the clinical-stage biotechnology company seeks to transition from development to potential commercialization in a rare-disease market where approved therapies are currently unavailable.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.